WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, is pleased to announce that Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of the Company's Series A non-voting preferred shares, each share of which shall be co ...

- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- "We are excited by this strategic investment from Sanofi, one of the world's leading biopharmaceutical companies, for our research and development programs," said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "We view Sanofi's investment in Vigil as a validation of our promising precision medicine approach led by our two differentiated TREM2 modalities, iluzanebart and VG3927 ...

Availability of the Q2 2024 Aide-mémoire About Sanofi Investor Relations Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com Alizé Kaisserian|+ 33 6 47 04 12 11 | alize.kaisserian@sanofi.com Arnaud Delépine |+ 33 6 73 69 36 93 | arnaud.delepine@sanofi.com Felix Lauscher |+ 1 908612 7239 | felix.lauscher@sanofi.com Keita Browne |+ 1 781 249 1766 | keita.browne@sanofi.com Nathalie Pham|+ 33 7 85 93 30 17 | nathalie.pham@sanofi.com Tarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.com Thi ...

Seven oral presentations across the hemophilia portfolio reinforce Sanofi's commitment to bring potential first- and best-in-class treatments to the rare blood disorders community Interim results from the long-term XTEND-ed phase 3 study demonstrate once-weekly ALTUVIIIO continues to provide highly effective bleed protection New ATLAS phase 3 study data reinforce the potential of fitusiran to provide prophylaxis for people with hemophilia A or B, with or without inhibitors New Drug Application for fitusiran ...

STOCKHOLM, June 19, 2024 /PRNewswire/ -- Sobi® today announced the European Commission has granted Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity. Children, adolescents, and adults can experience non-haemophilia factor VIII activity levels (above 40%) for a significant part of the week with once-weekly proph ...

"We look forward to combining the powerful capabilities of Belharra's next-generation chemotherapeutics platform with Sanofi's vast expertise in immunology research and development as we work together toward discovering new therapeutics for challenging-to-treat diseases," said Jeff Jonker, CEO of Belharra. "With the ability to illuminate any pocket, on any protein, in any cell type, our platform enables perhaps the broadest and most unbiased chemoproteomic screening capabilities in the industry. Leveraging ...

r th I t L 1 The Proper th i Commercial business is performing well "We are all-in on immunology, across therapeutic areas." We are all-in on Immunology, across therapeutic areas Unprecedented pipeline of blockbuster opportunities Amlitelimab shows significant improvements in signs In addition to the healthy immunology pipeline, we should see business development transactions that should complement the product portfolio and pipeline. Management seems more focused on bolt-on deals in the range EUR2 billion t ...

Investment thesis Wall Street's indifference to France's largest pharmaceutical company is reflected in its share price continuing to move sideways despite its rich pipeline of approved and experimental medicines, rising dividend payouts, and relatively low debt. In my estimation, in addition to the product candidates, some of which could become "gold standards" in the treatment of autoimmune diseases, other key contributors to strengthening Sanofi's balance sheet are innovative drugs such as Dupixent, Nexv ...

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% versus VRd followed by Rd in the investigational use for transplant-ineligible newly diagnosed multiple myeloma patients Key primary endpoint of progression-free surv ...

Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi's global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to secure that employees benefit from the company growth and success. Paul Hudson Chief Executive Officer of Sanofi "This plan underscores our ongoing commitment to unite the people of Sanofi behind our l ...